Research Use Disclaimer
This content is provided for educational and informational purposes only. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease. All information is presented in a research context.
What is LL37?
LL37 is discussed in biomedical literature as a human antimicrobial peptide and is often mentioned alongside cathelicidin-related terminology. This page provides a research-framed overview: definitions, common research questions, and the uncertainty boundaries that keep interpretation honest.
Key Takeaways
- This peptide is discussed in innate immunity and inflammation research contexts.
- Evidence strength varies by model, endpoints, and reporting standards.
- Identity/quality issues can distort reported outcomes when materials are not verified.
- For safety framing, read LL37 side effects.
- For methods framing, read LL37 dosage (conceptual).
- For compliance framing, see is LL37 legal (general overview; not legal advice).
Evidence Strength (How to Read Sources)
Stronger sources
- peer-reviewed papers with clear methods and endpoints
- explicit material identity and traceability language
- cautious conclusions aligned to the data
Weaker sources
- anecdotes without verification of identity, route, or confounders
- marketing copy that implies certainty without citations
- summaries that skip limitations
Data Table (Quick Facts)
| Aspect | What to check | Why it matters |
|---|
| Terminology | cathelicidin vs peptide naming | prevents mixing concepts across papers |
| Evidence type | in vitro / animal / human | changes what can be concluded |
| Endpoint | what was measured and when | avoids overgeneralization |
| Identity docs | batch/lot, traceability | reduces quality/contamination uncertainty |
Mechanism (High-Level, Non-Claim)
Mechanism sections are often written as if they were outcomes. A safer approach is:
- state mechanism as a hypothesis
- connect it to the type of endpoint a study measured
- avoid extrapolating preclinical observations to humans
Safety Snapshot
Next pages:
- Side effects: /peptides/ll37/side-effects/
- Dosage: /peptides/ll37/dosage/
- Legality: /peptides/ll37/legality/
FAQ
Q1: What is LL37? A1: LL37 is a human antimicrobial peptide (often discussed in relation to the cathelicidin family) that appears in innate immunity and inflammation research.
Q2: Where can I read LL37 side effects? A2: See LL37 side effects: /peptides/ll37/side-effects/.
Q3: Where can I read LL37 dosage context? A3: See LL37 dosage: /peptides/ll37/dosage/ (research framing; not instructions).
Q4: Is LL37 legal? A4: See is LL37 legal: /peptides/ll37/legality/ (general overview; not legal advice).
Q5: How should I interpret conflicting sources? A5: Check study design, endpoints, identity verification, and confounders before drawing conclusions.
Q6: What makes a page “referenceable” for SEO/AI summaries? A6: Clear takeaways, a table, citations, and explicit limitations (what is known vs unknown).
Q7: Does this page provide medical guidance? A7: No. This is an informational research overview only.
Additional Notes (Interpretation)
How to read this section
This section exists to make the page more referenceable without adding medical instructions. It focuses on interpretation: what a claim depends on, and what questions to ask before trusting a summary.
Why pages disagree
Two sources can sound contradictory while both being technically correct because they describe different models, endpoints, time windows, or definitions. Prefer primary literature with clear methods and explicit limitations over generalized summaries.
Quality & identity checklist
- Verify terminology (aliases, fragments, naming conventions)
- Check the study type (in vitro / animal / human)
- Look for endpoint clarity (what was measured and when)
- Confirm identity/traceability signals when relevant (batch/lot, documentation)
References
- Rosacea: Pathogenesis and Therapeutic Correlates. *2024 Mar-Apr;28(2):178-189* (2024). https://pubmed.ncbi.nlm.nih.gov/38450615/ (DOI: https://doi.org/10.1177/12034754241229365)
- Vitamin D, infections and immunity. *2022 Apr;23(2):265-277* (2022). https://pubmed.ncbi.nlm.nih.gov/34322844/ (DOI: https://doi.org/10.1007/s11154-021-09679-5)
- Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation. *2023 Apr 5:14:1151926* (2023). https://pubmed.ncbi.nlm.nih.gov/37090695/ (DOI: https://doi.org/10.3389/fimmu.2023.1151926)
- Signaling pathways and targeted therapy for rosacea. *2024 Sep 16:15:1367994* (2024). https://pubmed.ncbi.nlm.nih.gov/39351216/ (DOI: https://doi.org/10.3389/fimmu.2024.1367994)
- Impact of vitamin D status and cathelicidin antimicrobial peptide on adults with active pulmonary TB globally: A systematic review and meta-analysis. *2021 Jun 11;16(6):e0252762* (2021). https://pubmed.ncbi.nlm.nih.gov/34115790/ (DOI: https://doi.org/10.1371/journal.pone.0252762)
- Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury. *2019 Feb 20;17(1):42* (2019). https://pubmed.ncbi.nlm.nih.gov/30782145/ (DOI: https://doi.org/10.1186/s12916-019-1268-y)
Internal Links